➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Moodys
Dow
Boehringer Ingelheim

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,691,847

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,691,847 protect, and when does it expire?

Patent 8,691,847 protects BEVYXXA and is included in one NDA.

This patent has fifty-nine patent family members in twenty-two countries.

Summary for Patent: 8,691,847
Title:Benzamides and related inhibitors of factor Xa
Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inventor(s): Zhu; Bing-Yan (Palo Alto, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (East Brunswick, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (Concord, CA), Li; Wenhao (Union City, CA), Zuckett; Jingmei (Bellevue, WA), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/612,597
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,691,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial Y Y PROPHYLAXIS OF VENOUS THROMBOEMBOLISM   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial Y Y PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial Y Y PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial Y Y PROPHYLAXIS OF VENOUS THROMBOEMBOLISM   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Boehringer Ingelheim
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.